

PAPERS

Published

1. Caygill CPJ, Reed PI, McIntyre A, Hill MJ (1998). The UK National Barrett's Oesophagus Registry: A Study Between Two Centres. *Eur J. Cancer Prev*; **7**: 161-164.
2. Caygill CPJ, Reed PI, Johnston BJ, Hill MJ, Ali M, Levi S (1999). A single centre's 20 years' experience of columnar-lined (Barrett's) oesophagus diagnosis. *Eur J Gastro and Hep* **11**: 1355 - 1358.
3. Caygill CPJ, Reed PI, Hill MJ, Watson A (1999) An initial comparison of nine centres registering patients with the UK National Barrett's Oesophagus Registry (UKBOR). *Eur J. Cancer Prev*; **8**: 539-542.
4. Caygill CPJ, Johnston DA, Lopez M, Johnston BJ, Watson A, Reed PI, Hill MJ. (2002). Lifestyle Factors and Barrett's Oesophagus. *Amer J Gastroenterology* **97**: 1328-1331.
5. Caygill CPJ, Watson A, Reed PI, Hill MJ (on behalf of the UK National Barrett's Oesophagus Registry (UKBOR) and the twenty seven participating centres) (2003). Characteristics and Regional Variations of Patients with Barrett's oesophagus in the UK. *Eur J Gastro Hep* **15**: 1217-1222.
6. Van Blankenstein M, Looman CWN, Johnston BJ, Caygill CPJ (2005). Age and sex distribution of the prevalence of Barrett's Esophagus found in a primary referral endoscopy center. *Amer J Gastroenterology* **100**: 568-576.
7. Ramus JR, Gatenby PAC, Caygill CPJ, Watson A (2007) Helicobacter Pylori infection and severity of reflux-induced oesophageal disease in a cohort of patients with Columnar-Lined Oesophagus *Dig Dis Sci* **52**: 2821-2825 .

8. Gatenby PAC, Caygill CPJ, Ramus J R, Charlett A, Watson A (2007) Short Segment Columnar-Lined Oesophagus (CLO) - an underestimated cancer risk? A large cohort study of the relationship between Barrett's CLO segment length and adenocarcinoma risk. *Eur J Gastro Hep* **19**: 969-975.
9. Gatenby PAC, Ramus JR, Caygill CPJ, Watson A (2007). Does the length of columnar-lined esophagus change with time? *Dis Oesophagus* **20**: 497-503.
10. Ramus JR, Caygill CPJ, Gatenby PAC, Watson A (2008) Current UK practice in the diagnosis and management of columnar-lined oesophagus; results of the UK National Barrett's Oesophagus Registry (UKBOR) endoscopist questionnaire. *Eur J Cancer Prev* **17**: 422-425.
11. Gatenby PAC, Caygill CPJ, Ramus J R, Charlett A, Watson A (2008). Barrett's Columnar-Lined Esophagus: Demographic and Lifestyle Associations and Adenocarcinoma Risk *Digestive Diseases and Sciences* **53**: 1175-85.
12. Gatenby PAC, Ramus JR, Caygill CPJ, Shepherd NA, Watson A (2008). The Relevance of the Detection of Intestinal Metaplasia in Non-Dysplastic Columnar-Lined Oesophagus. *Scand J Gastro* **43**: 524-530
13. Gatenby PAC, Ramus JR, Caygill CPJ, Charlett A, Winslet MC, Watson A (2009). Treatment modality and risk of development of dysplasia and adenocarcinoma in columnar-lined esophagus. *Dis Oesophagus* **22**: 133-42
14. Ramus JR, Gatenby PAC, Caygill CPJ, Winslet MC, Watson A (2009) Surveillance of Barrett's columnar-lined oesophagus in the UK: endoscopic intervals and frequency of detection of dysplasia. *Eur J Gastro Hep* **21**: 636-641.
15. Wall CM, Charlett A, Caygill CPJ, Gatenby PAC, Ramus JR, Winslet M, Watson A. (2009) Are Newly Diagnosed Columnar-lined Oesophagus(CLO) Patients

Getting Younger? Eur J Gastro Hep **21**: 1127-1131.

16. Gatenby PAC, Ramus JR, Caygill CPJ, Charlett A, Winslet MC, Watson A (2009). The Influence of Symptom Type and Duration on the Fate of the Metaplastic Columnar-Lined Oesophagus. Aliment Pharmacol Ther **29**: 1096-1105.

17. Gatenby PAC, Ramus JR, Caygill CPJ, Shepherd NA, Winslet MC, Watson A (2009). Routinely diagnosed low grade dysplasia in Barrett's oesophagus: A population-based study of natural history. Histopathology **54**:814-9

18. Gatenby PAC, Ramus JR, Caygill CPJ, Winslet MC, Watson A (2009). Aspirin is not chemoprotective for Barrett's adenocarcinoma of the oesophagus in a multicentre cohort. Eur J Cancer Prev **18**:381-384

19. Gatenby P, Hainsworth A, Caygill C, Watson A, Winslet M (2011) Projections for oesophageal cancer incidence in England to 2033. Eur J Cancer Prev **20**: 283-286.

20. Caygill CPJ, Royston C, Charlett A, Wall CM, Gatenby PAC, Ramus JR, Watson A, Winslet M, Hourigan CS, BardhanKD (2011). Barrett's, blood groups and progression to oesophageal cancer: Is nitric oxide the link? Eur J Gastro Hep **23**: 801-806.

21. Ramus JR, Gatenby PAC, Caygill CPJ, Watson A, Winslet M (2012). The relationship between smoking and dysplastic disease in patients with columnarised oesophagus (CLO). Eur J Cancer Prev **21**: 507-510.

22. Caygill CPJ, Royston C, Charlett A, Wall CM, Gatenby PAC, RamusJR, Watson A, M. Winslet M, Bardhan KD (2012) Mortality in Barrett's Oesophagus: Three decades of experience in a single centre. Endoscopy **44**: 892-898

23. Gatenby P, Caygill C, Wall C, Bhattacharjee S, Ramus J, Watson A, Winslet M. (2014). Lifetime risk of esophageal adenocarcinoma in patients with Barrett's esophagus (columnar-lined esophagus). World Journal of

Gastroenterology **20**: 9611-9617.

24. Bhattacharjee S, Caygill CPJ, Charlett A, Fox AJ, Gatenby PAC, Watson A, Royston C, Bardhan KD. (2016). The socioeconomic profile of a Barrett's oesophagus cohort assessed by the 2010 Index of Multiple Deprivation. Eur J Gastro Hep **28**: 199 - 204

25. Royston C, Caygill C, Charlett A, Bardhan KD. (2016). The evolution and outcome of surveillance of Barrett's oesophagus over four decades in a UK District General Hospital. Eur J Gastroenterol Hepatol **28**: 1365-1373.

MD/PhD THESES

1. Gatenby PAC (2008). The Natural History of Columnar-Lined Oesophagus, University of London.

2. Ramus JR (2008). Barrett's oesophagus and its progression to adenocarcinoma: A study of patient profile. University of London.

3. Alexandre L (2017) The potential role of statins in the treatment and prevention of oesophageal adenocarcinoma. Norwich Medical School, University of East Anglia.

LETTERS

1. Caygill CPJ (1999). Treating upper digestive track cancers as a single entity may be misleading. British Medical Journal (BMJ) **318**, 1289-90.

2. Caygill CPJ, Watson A (2006) The association of body mass index with Barrett's oesophagus. Aliment Pharmacol Ther **23**, 1027-1028.

3. Caygill CPJ, Royston C, Charlett A, Wall CM, Gatenby PAC, Ramus JR, Watson A, Winslet M, Bardhan KD

(2013). Mortality in Barrett's Oesophagus: Three decades of experience in a single centre – Reply to Schoppman et al. *Endoscopy* **45**: 153

INVITED PAPERS

1. Caygill CPJ, Reed PI, Watson A, Hill MJ. (2000). The UK National Barrett's Oesophagus Registry (UKBOR): aims and progress. *Eur J Cancer Prev.* **10**: 97-99.
2. Caygill CPJ (2001). Barrett's Oesophagus and Oesophageal Adenocarcinoma: the Epidemiological Evidence. *Acta Endoscopica* **31**, 485-490.
3. Caygill C PJ, Gatenby PAC, Watson A (2011). Should a decision of surveillance be based upon the presence of an intestinal metaplasia at endoscopy, also taking into consideration potential sampling errors? In Barrett's Esophagus: surveillance and reversal. Caygill C PJ, Dvorak K, Triadafilopoulos G, Felix VN, Horwhat JD, Hwang JH, Upton MP, L X, Nandurkar S, Gerson LB, Falk GW. *Ann NY Acad Sci*, 1232 Issue Barrett's Esophagus; pp 197-198. Publishers New York Academy of Sciences.
4. Gatenby PAC, Caygill CPJ, Watson A (2011). Do Barrett's registries have a role to play in research? In Barrett's esophagus registries. Gatenby PAC, Caygill CPJ, Watson A, Murray L, Romero Y. *Ann NY Acad Sci*, 1232 Issue Barrett's Esophagus; pp 406-407. Publishers New York Academy of Sciences.
5. Romero Y, Caygill CPJ (2011). Barrett's registries: what are the demographic, lifestyle, and diagnostic differences between the United States and Europe, and can these be overcome for future collaborative studies? In Barrett's esophagus registries. Gatenby PAC, Caygill CPJ, Watson A, Murray L, Romero Y. *Ann NY Acad Sci*, 1232 Issue Barrett's Esophagus; pp 408-410. Publishers New York Academy of Sciences.
6. Caygill CPJ, Watson A, Reed PI (2012). Barrett's oesophagus: raising awareness in heartburn sufferers. *Trends in Urology & Mens Health*; 3: 22-24.

7. Caygill CPJ, Gatenby PAC, Herceg Z, Lima SCS, Pinto LFR, Watson A, Wu MS (2014) 'How does the UK Barrett's Registry (UKBOR) operate?' In comparative genomic analysis of esophageal cancers NY Acad Sci, **1325**: p74

8. Watson A, Galloway J (2014). Heartburn, Barrett's oesophagus and cancer. Brit J Gen Practice; 64: 120-121.

9. Caygill CPJ, Gatenby PAC, (2014). Radiofrequency ablation of Barrett's oesophagus with confirmed low-grade dysplasia reduces risk of development of high-grade dysplasia and adenocarcinoma. Evidence-based Medicine doi: 10. 1136/ebmed-2014-110019

INVITED REVIEWS

1. Reed PI, Caygill CPJ, Watson A (2003). The United Kingdom Barrett's Oesophagus Registry (UKBOR) - the first six years. Gastroenterologia Polska **10**: 299-304.

2. Caygill CPJ, Watson A, Lao-Sirieix P, (2004). Barrett's Oesophagus and Adenocarcinoma. World Journal of Surgical Oncology **2**: 12. (Web publication)
www.wjso.com/content/2/1/12.

REPORTS

1. Caygill CPJ, Zaninotto G, Ruge M (2008) Barrett's Registries in Europe: Report of an International Workshop. Eur J Cancer Prev. **17**: 426- 429.

ABSTRACTS AND POSTERS

Published:

1. Caygill CPJ, Reed PI, Hill MJ, Watson A (1997). The UK National Barrett's Oesophagus Registry. Gut **40** (suppl.1): A35.

2. Caygill CPJ, Reed PI, Johnston, BJ, Hill MJ, Levi S (1997). A Study of Barrett's Oesophagus Registrations From a Single Centre Over a 20 Year Period. Gut **41**

(suppl.3): E43.

3. Caygill CPJ, Reed PI, Watson A, McIntyre A, Hill MJ (1998). The First Year of the UK National Barrett's Esophagus Registry. *Gastroenterology* **114**, A87
4. Reed PI, Caygill CPJ, Hill MJ, Watson A (1998). The UK National Barrett's Oesophagus Registry (UKBOR): The first Two Years. *Eur. J. Surgical Oncology* **24**, 457.
5. Caygill CPJ, Reed PI, Hill MJ (1998).UK National Barrett's Oesophagus Registry: A Comparison of Nine Centres. *Digestion* **59** (suppl. 3):580.
6. Watson A, Reed PI, Caygill CPJ, Epstein O, Winslet MC, Pounder RE (1999). Changing incidence of columnar-lined (Barrett's) oesophagus (CLO) in the UK. *Gut* **44**, Suppl. 1, A45
7. Caygill CPJ, Reed PI, Johnston BJ, Hill MJ, Deru K, Watson A, Levi S (1998) UK National Barrett's Oesophagus Registry: role of obesity, tobacco and alcohol in Barrett's oesophagus. *Eur. J. Cancer Prev.* **7**, 481
8. Watson A, Reed PI, Caygill CPJ, Epstein O, Winslet MC, Pounder RE (1999). Changing incidence of columnar-lined (Barrett's) oesophagus (CLO) in the UK. *Gastroenterology* **116**, Suppl 2, A351.
9. Caygill CPJ, Jankowski J, Ali M, Reed PI, Hill MJ (1999). Expression of Bile Acid Receptors: A preliminary report. *Eur. J. Cancer Prev.***8**, 354.
10. Caygill CPJ, Reed PI, Hill MJ, Watson A (1999). The UK National Barrett's Oesophagus Registry: a Progress Report.. *Eur. J. Cancer Prev.* **8**, 354
11. Caygill CPJ, Reed PI, Johnston DA, Lopez M, Hill MJ (1999) Obesity and Barrett's oesophagus in a UK Population. 1999. *Gut.* **45**, A81.
12. Caygill C, Reed P, Watson A, Hill M (2000). UK National Barrett's Oesophagus Registry: An Update. *Eur.*

J Cancer Prev. **9**: 456-7.

13. Caygill C, Reed P, Watson A, Hill M (2000). UK National Barrett's Oesophagus Registry: An Update. Gut **47**, (suppl. III) A68.

14. Watson A, Caygill CP (2002). The frequency of development of adenocarcinoma in Barrett's oesophagus – implications for surveillance. Gastroenterology **122**: A350.

15. Van Blankenstein M, Caygill CPJ, Johnston BJ (2002). The prevalence of Barrett's oesophagus (BO) in an U.K. Centre over 15 years. Gut **50**, (suppl. II) A123

16. Gatenby PAC, Caygill CPJ, Charlett A, Watson A (2003) Length of Barrett's Oesophagus Segment: Demographic Associations and Cancer Risk. Gut **52**: (suppl. I) A41.

17. Gatenby PAC, Caygill CPJ, Watson A, Charlett A (2003) Length of Barrett's Oesophagus Segment: Demographic Associations and Cancer Risk. Gastroenterology **124**: A638.

18. Gatenby P, Caygill C, Ramus J, Bateson M, Johnston D, Watson A (2003) Distribution of obesity by age and gender in Barrett's oesophagus patients at two culturally different centres registering with UK National Barrett's Oesophagus Registry. J Clin Oncology **38**: 185 (P57). (Selected for oral presentation at plenary session)

19. Gatenby PAC, Ramus JR, Caygill CPJ, Watson A (2003). Association Between Lifestyle Factors and Histology in Barrett's Oesophagus. Gut **52**: (suppl VI) A221.

20. Gatenby PAC, Caygill CPJ, Ramus JR, Watson A (2004). Metaplasia-Dysplasia-Adenocarcinoma Sequence in Barrett's Oesophagus (CLO) in a Large UK Series. Gut **53**: (suppl III) A55.

21. Gatenby PAC, Caygill CPJ, Ramus JR, Watson A (2004). Does the Length of the Columnar-lined

Oesophagus (CLO) Change with Time. Gut **53**: (suppl III) A35. (Selected for plenary session).

22. Gatenby PAC, Ramus JR, Caygill CPJ, Watson A (2004). Incidence of adenocarcinoma in short and long segment columnar-lined oesophagus. Gastroenterology **126**: (suppl 2) A308. (awarded a distinction).

23. Gatenby PAC, Caygill CPJ, Ramus JR, Watson A (2004). Does the length of columnar-lined oesophagus (CLO) change with time. Gastroenterology **126**: (suppl 2) A177. (selected as a poster of special interest).

24. Gatenby PAC, Ramus JR, Caygill CPJ, Watson A (2004). Histological Sequence in a Large UK Series of Columnar-Lined Oesophagus (CLO). Diseases of the Esophagus **17**: (suppl 1) A22

25. Gatenby PAC, Ramus JR, Caygill CPJ, Watson A (2004). Histological Sequence in a Large UK Series of Columnar-Lined Oesophagus (CLO). Diseases of the Esophagus **17**: (suppl 1) A126-7

26. Gatenby PAC, Ramus JR, Caygill CPJ, Watson A (2004). Adenocarcinoma (AC) Risk in Short (SS) and Long (LS) Segment Columnar-Lined Oesophagus (CLO). Diseases of the Esophagus **17**: (suppl 1) A46-7

27. Gatenby PAC, Ramus JR, Caygill CPJ, Watson A (2004). Adenocarcinoma (AC) Risk in Short (SS) and Long (LS) Segment Columnar-Lined Oesophagus (CLO). Diseases of the Esophagus **17**: (suppl1) A127.

28. Gatenby PAC, Ramus JR, Caygill CPJ, Watson A (2004). Change in Length of the Columnar-Lined Oesophagus (CLO) over Time and Cancer Risk. Diseases of the Esophagus **17**: (suppl1) A16.

29. Gatenby PAC, Ramus JR, Caygill CPJ, Watson A (2004). Time course of metaplastic and dysplastic changes in columnar-lined oesophagus (CLO) and relationship to symptom onset. Accepted by UEGW Sep. 2004. Gut **53** (suppl VI) A99.

30. Gatenby PAC, Ramus JR, Caygill CPJ, Watson A (2004). Relationship of presenting symptoms to outcome in columnar-lined oesophagus (CLO). Gut **53** (suppl VI) A101.
31. Ramus JR, Gatenby PAC, Caygill CPJ, Watson A (2004). Helicobacter pylori infection and severity of oesophageal disease in a cohort of patients with Barrett's oesophagus. Accepted by UEGW for oral presentation. Gut **53** (suppl VI) A61.
32. Gatenby PAC, Ramus JR, Caygill CPJ, Watson A (2005). Impact of treatment on Barrett's Cancer incidence. Gut **54** (suppl 11) A52.
33. Gatenby PAC Caygill CPJ, Ramus JR, Watson A (2005). Barrett's oesophagus treatment: effect on high grade dysplasia – oesophageal cancer incidence. Gastroenterology **128**, (suppl 2), S1713.
34. Gatenby PAC, Caygill CPJ, Ramus JR, Shepherd N, Watson A (2005). The significance of detection of intestinal metaplasia (IM) in columnar-lined oesophagus (CLO). The Canadian J of Gastroenterology HOME **WCOG abstracts** R0078.
35. Ramus JR, Gatenby PAC, Caygill CPJ, Watson A (2005). Endoscopic surveillance intervals for columnar-lined oesophagus (CLO) in the U.K. and Impact on detection of dysplastic disease. The Canadian J of Gastroenterology HOME **WCOG abstracts** R0090.
36. Ramus JR, Caygill CPJ, Gatenby PAC and Watson A. (2006). Diagnosis and management of Barrett's oesophagus; results of the UK National Barrett's Oesophagus Registry (UKBOR) endoscopist questionnaire. Gut **55** (suppl 11) A104-105.
37. Wall C, Charlett A, Caygill C, Gatenby P, Ramus J, Watson A (2006). Are newly diagnosed columnar-lined oesophagus patients getting younger? J Clin Gastroenterol **40** (suppl 4) S207.
38. Gatenby P, Ramus J R, Caygill C P J, Watson A

(2007). The Relevance of Low-grade Dysplasia in Columnar-lined Oesophagus. Gut **56** (suppl 11) A70.

39. Gatenby P, Ramus J R, Caygill C P J, Watson A (2007). The Outcome of Low-Grade Dysplasia in Barrett's Columnar-Lined Esophagus - A large cohort study from the UK National Barrett's Oesophagus Registry. Gastrointestinal Endoscopy **65**: AB133

40. Gatenby PAC; Ramus JR; Caygill CPJ; Winslet MC; Watson A (2008). No Evidence of Aspirin Chemoprotection in Barrett's Adenocarcinoma of the Esophagus? Gastrointestinal Endoscopy **67**: AB178 – AB179

41 Caygill, CPJ, Charlett A, Wall C, Bardhan KD, Royston C, Gatenby P, Ramus JR, Winslet M (2009) Blood group distribution in reflux disease, columnar-lined oesophagus and oesophageal adenocarcinoma compared with the blood donating population. Gastroenterology **136**: (Supple 1) A601.

42 Ramus JR, Gatenby PAC, Caygill CPJ, Watson A, Winslet M (2009) The risk of smoking on development of dysplastic disease in patients with columnarised oesophagus. Presented at World Congress of Gastroenterology.

43. Caygill CPJ, , Royston C, Charlett A, Wall CM, Gatenby PAC, Ramus JR, Watson A, Winslet M, Bardhan K (2010). Mortality in patients with columnar-lined oesophagus (CLO) Gastroenterology 2010; 138: S-16 (accepted for oral presentation).

44. Gatenby P, Ramus J, Caygill C, Wall C, Hainsworth A, Watson A, Winslet M (2010). Columnar-Lined Oesophagus Segment Length and High-Grade Dysplasia and Adenocarcinoma Risk. J Clinl Gastroenterol 2011; 45: A039.

45. Gatenby P, Caygill C, Ramus J, Wall C, Watson A, Winslet M (2010) Same risk of dysplasia but decreasing risk of cancer in Barrett's oesophagus. J Clinl

Gastroenterol 2011; 45: A038.

46. Gatenby P, Hainsworth A, Caygill C, Watson A, Winslet M (2010) Projections for oesophageal cancer incidence in England. J Clinl Gastroenterol 2011; 45: A030.

47. Gatenby P, Caygill CP, Wall C, Bhattacharjee S, Ramus J, , Watson A, Winslet MC and on behalf of the 35 collaborating centres (2011). Lifetime risk of oesophageal adenocarcinoma in patients with Barrett's columnar-lined oesophagus registered with UK National Barrett's Oesophagus Registry. Gut 2011; 60: A35.-A36.

48. Gatenby P, Caygill CP, Wall C, Bhattacharjee S, Ramus J, , Watson A, Winslet MC and on behalf of the 35 collaborating centres (2011). Lifetime risk of Esophageal Cancer and Endoscopic Surveillance Burden in UK Patients with Barrett's Esophagus. Gastroenterology 2011; 140: S222-S223

49. Gatenby P, Ramus J, Bhattacharjee S, Wall C, Caygill C, Watson A (2013) Examination of the Time Trends in Dysplasia and Cancer Incidence in Barrett's Oesophagus Results From a Large Multicentre Cohort Study Oeso World conference (shortlisted for prize)

50. Caygill CPJ, Bhattacharjee S, Charlett A, Fox AJ, Gatenby PAC, Watson A, Royston C, Bardhan. KD. Index of social deprivation in a Barrett's esophagus cohort: the influence of affluence? Gastroenterology 2014; 146: s312 (poster of distinction)

51. Caygill C, Bhattacharjee S, Charlett A, Fox AJ, Gatenby P, Watson A, Royston C, Bardhan KD. Social deprivation in Barrett's oesophagus? Gut 2014; 63:A117-A118

52. Bhattacharjee S , Caygill CPJ , Gatenby PAC , Watson A. Social Class Distribution of Patients with Barrett's Esophagus and Esophageal Adenocarcinoma. Gastroenterology 2016; 150 (suppl 1): S262 – S263.

53. Bhattacharjee S , Caygill CPJ , Gatenby PAC , Watson A. Social Class and Progression of Barrett's Oesophagus to Oesophageal Adenocarcinoma. Gut 2016; 65 (suppl 1):A135

54. Royston C, Charlett A, Caygill CP, Bardhan KD The Rotherham Barrett's Oesophagus Surveillance programme. The Final Outcome after 37 years. Gut 2016; 65: A129.

55. Alexandre L, Royston C, Caygill C, Bhattacharjee s, Bardhan C, Clark A, Watson A, Hart A. Statin use and malignant progression in patients with non-dysplastic barratt's oesophagus: a nested case-control study. Gut 2017; 66: A192-A193

BOOK CHAPTERS

1. Caygill C, Hill M (2005). Bacteria and cancer. In Advances in molecular and cellular pathology, Lax A (Ed).Cambridge University Press, Cambridge, p199-225.

2. Caygill CPJ, Gatenby PAC (2012). Epidemiology of the association between bacterial infections and cancer In Bacteria and cancer, Khan AA (Ed). Springer, p1-24.

Notes

1. Reed PI, Watson A (1996). UK National Barrett's Oesophagus Registry. Gut; **39**: 499-500.

2. Reed PI, Watson A (1996). UK National Barrett's Oesophagus Registry. Eur J Cancer Prev; **5**: 207.

3. Salmon P (2007) Barrett's Oesophagus Foundation. Gastrointestinal Nursing; **5**: 14-17.

4. Research Highlights (2011). Blood group linked to risk of cancer in patients with Barrett's oesophagus. Nature Reviews Gastroenterology & Hepatology **8**: 457.

5. 1 Shukla M, 2 RoychowdhuryM, 3 Singh S, 4Caygill C, 5. Lillard JW, Jr, 6 Singh S, 7 Tiwar SKi, 8 Verm V, 9,10

Pandey. (2017). Menace of Simultaneous Duplicate Submissions: A consensus Statement. *World J Pathology*; **6**: 17-19.

1. Editor-in-Chief, *World Journal of Pathology*, 2 Editor-in-Chief, *World Journal of Medical and Surgical Case Reports*, 3 Editor-in-Chief, *World Journal of Basic and Applied Science*, 4 Editor-in-Chief, *World Journal of Epidemiology and Cancer Prevention*, 5 Editor-in-Chief, *World Journal of Medical Research*, 6 Editor-in-Chief, *World Journal of Minimal Access Surgery*, 7 Editor-in-Chief, *World Journal of Surgical Research*, 8 Editor-in-Chief, *World Journal of Trauma and Critical Care Medicine*, 9 Editor-in-Chief, *World Journal of Psycho-Social Oncology*, 10 Editor-in-Chief, *World Journal of Surgical Medical and Radiation Oncology*.

Research Contributions/Workshops

1. Research Priority Setting in Barrett's Oesophagus and Gastroesophageal Reflux Disease. Britton J, Gadeke L, Lovat, L Hamdy S, Hawkey C, McLaughlin J, Ang Y (2017). *Lancet Gastroenterology and Hepatology* 2017, 2: 824-831.